Hemispherx Biopharma Inc. (HEB)

4.37
AMEX : Health Technology
Prev Close 4.32
Day Low/High 4.20 / 4.67
52 Wk Low/High 3.62 / 14.81
Avg Volume 4.53M
Exchange AMEX
Shares Outstanding 2.20M
Market Cap 9.51M
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Insider Trading Alert - HEB, EPAY And STOR Traded By Insiders

Insider Trading Alert - HEB, EPAY And STOR Traded By Insiders

Stocks with insider trader activity include HEB, EPAY and STOR

Hemispherx Biopharma Reviews Ampligen® Data With National Institute Of Neurological Disorders And Stroke (NINDS)

Hemispherx Biopharma Reviews Ampligen® Data With National Institute Of Neurological Disorders And Stroke (NINDS)

National Institutes of Health Research Focus on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is Set to be a Game Changer for Patients

Hemispherx Biopharma Introduces A Voluntary Stock Purchase Plan To Create Shareholder Value

Hemispherx Biopharma Introduces A Voluntary Stock Purchase Plan To Create Shareholder Value

Senior Management, Entire Board of Directors, and 100% of All Employees Participate

Hemispherx Biopharma Announces Financial Results For The Nine Months Ended September 30, 2015

Hemispherx Biopharma Announces Financial Results For The Nine Months Ended September 30, 2015

Long Term Exclusivity in Promising Novel Nucleic Acid Treatments Supported by Recent Issuance of a Broad Patent in European Union

Hemispherx Biopharma Reports Low NK Cell Activity In Chronic Fatigue Syndrome (CFS) And Relationship To Disease Symptoms

Hemispherx Biopharma Reports Low NK Cell Activity In Chronic Fatigue Syndrome (CFS) And Relationship To Disease Symptoms

Ampligen(R) Increases NK Activity More Than 100% in Vitro in a CFS Patient Population

Hemispherx Biopharma's Judgment Unanimously Affirmed Against Cato Capital

Hemispherx Biopharma's Judgment Unanimously Affirmed Against Cato Capital

Company to Update and Pursue Collection of at Least $770,852.76 in Attorney Fees and Costs Awarded to it in Delaware Contract Dispute

Hemispherx Biopharma Enters Into Direct Supply Agreement With Gulf Coast Regional Blood Center To Supply Leukocytes To Manufacture Alferon N Injection(R)

Hemispherx Biopharma Enters Into Direct Supply Agreement With Gulf Coast Regional Blood Center To Supply Leukocytes To Manufacture Alferon N Injection(R)

Important First Step to Resolve Raw Material Supply Delays Associated With BioLife Plasma Services' Breach of Long Term Supply Agreement With Hemispherx

Insider Trading Alert - SKT, HEB And NURO Traded By Insiders

Insider Trading Alert - SKT, HEB And NURO Traded By Insiders

Stocks with insider trader activity include SKT, HEB and NURO

Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care For Alferon N Injection(R)

Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care For Alferon N Injection(R)

Two-Year Extension Follows Completion of $8 Million Upgrade and Preparation for Re-Launch of Alferon N in the US

Hemispherx Biopharma Announces Financial Results For The Six Months Ended June 30, 2015

Hemispherx Biopharma Announces Financial Results For The Six Months Ended June 30, 2015

New Program Launched in Concert With Facilities Enhancement

Hemispherx Biopharma Board Appoints New President

Hemispherx Biopharma Board Appoints New President

Seasoned Executive With Extensive International Experience

Hemispherx Expands Its Collaboration With Emerge Health For The Commercialization Of Alferon In Australia And New Zealand

Hemispherx Expands Its Collaboration With Emerge Health For The Commercialization Of Alferon In Australia And New Zealand

Hemispherx and Emerge Health to Commence a Named Patient Program While Seeking Formal Regulatory Approval

TheStreet Quant Rating: E+ (Sell)